EUVIMEDEUVIMED entdecken
Crossref

Abstract 8980: Incremental Kidney and Glycemic Outcomes Associated with GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Therapy versus SGLT2 Inhibitor Monotherapy in Adults with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease

Emmanuel Adjei-Wiafe, George A Blankson, Emmanuel N Ansah, Edmond K Appiah, Christiana Kwakyewa Asihene, Paras Singh Chandi, Lord Nuhu Ibrahim, Yaw Ahenkora Amoakoh-Dua

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.8980 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Emmanuel Adjei-Wiafe und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with type 2 diabetes mellitus (T2DM), heart failure (HF), and chronic kidney disease (CKD) remain at high risk for renal deterioration, glycaemic emergencies, and adverse cardiovascular outcomes despite contemporary therapy. Although sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiorenal outcomes, the incremental benefit of adding glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy remains uncertain.

Objective

To compare renal, glycaemic, and cardiovascular outcomes between SGLT2i monotherapy and combined GLP-1RA/SGLT2i therapy in adults with T2DM, HF, and CKD.

Methods

We performed a retrospective propensity score-matched cohort study using the TriNetX Research Network. Adults aged ≥18 years with T2DM, HF, and CKD stages 3a-4 without baseline ESRD were included. Patients receiving GLP-1RA plus SGLT2i therapy were compared with those receiving SGLT2i monotherapy. After balancing demographics, comorbidities, and cardiovascular and diabetes medications using propensity score matching, 20,059 patients were included in each cohort from an initial population of 71,970 eligible patients. Outcomes were assessed from 30 days to 5 years after treatment initiation. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated for renal, glycaemic, cardiovascular, and mortality outcomes.

Results

Combination therapy was associated with lower risk of composite renal events (HR 0.894, 95% CI 0.853-0.937; p

Zitieren

APA

Adjei-Wiafe, E., Blankson, G. A., Ansah, E. N., Appiah, E. K., Asihene, C. K., Chandi, P. S., Ibrahim, L. N., & Amoakoh-Dua, Y. A. (2026). Abstract 8980: Incremental Kidney and Glycemic Outcomes Associated with GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Therapy versus SGLT2 Inhibitor Monotherapy in Adults with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.8980

Vancouver

Adjei-Wiafe E, Blankson GA, Ansah EN, Appiah EK, Asihene CK, Chandi PS, et al. Abstract 8980: Incremental Kidney and Glycemic Outcomes Associated with GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Therapy versus SGLT2 Inhibitor Monotherapy in Adults with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.8980

BibTeX
@article{AdjeiWiafe2026,
  author = {Adjei-Wiafe, Emmanuel and Blankson, George A and Ansah, Emmanuel N and Appiah, Edmond K and Asihene, Christiana Kwakyewa and Chandi, Paras Singh and Ibrahim, Lord Nuhu and Amoakoh-Dua, Yaw Ahenkora},
  title = {Abstract 8980: Incremental Kidney and Glycemic Outcomes Associated with GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Therapy versus SGLT2 Inhibitor Monotherapy in Adults with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.8980}
}
Kostenlos starten →